Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. trimmed its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 82.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,000 shares of the biotechnology company's stock after selling 176,630 shares during the quarter. D.A. Davidson & CO.'s holdings in Heron Therapeutics were worth $57,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. increased its stake in Heron Therapeutics by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock valued at $411,000 after purchasing an additional 154,487 shares during the last quarter. Principal Financial Group Inc. raised its stake in Heron Therapeutics by 456.5% during the 3rd quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock worth $204,000 after acquiring an additional 84,205 shares in the last quarter. Verition Fund Management LLC grew its holdings in shares of Heron Therapeutics by 340.0% during the third quarter. Verition Fund Management LLC now owns 108,115 shares of the biotechnology company's stock worth $215,000 after purchasing an additional 83,542 shares during the last quarter. Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics by 24.1% in the 4th quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock valued at $3,757,000 after purchasing an additional 477,417 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Heron Therapeutics by 29.8% in the 3rd quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock valued at $434,000 after purchasing an additional 50,109 shares during the period. 80.01% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

HRTX has been the subject of several research analyst reports. StockNews.com raised Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday. Needham & Company LLC reiterated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research note on Friday.

Heron Therapeutics Price Performance

Shares of HRTX stock traded down $0.23 during midday trading on Monday, hitting $2.25. The company had a trading volume of 2,913,155 shares, compared to its average volume of 1,786,977. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The company's 50 day simple moving average is $1.69 and its 200 day simple moving average is $1.71. The stock has a market cap of $341.45 million, a price-to-earnings ratio of -12.42 and a beta of 1.60.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. Analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.